Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, gives an overview of ongoing Phase III clinical trials evaluating ruxolitinib-based combinations in patients with myelofibrosis (MF). Prof. Kremyanskaya mentions the TRANSFORM-1 study (NCT04472598) which assesses the addition of navitoclax to ruxolitinib, as well as the MANIFEST-2 study (NCT04603495) testing the addition of pelabresib to ruxolitinib in treatment-naïve patients, and the LIMBER-313 (NCT04551066) and LIMBER-304 (NCT04551053) studies which are evaluating the addition of parsaclisib in newly diagnosed patients or patients who have a suboptimal response to ruxolitinib while receiving ruxolitinib monotherapy respectively. This interview took place virtually.

свернуть